BOOM

Trending Searches

    SUPPORT
    BOOM

    Trending News

      • Fact Check 
        • Fast Check
        • Politics
        • Business
        • Entertainment
        • Social
        • Sports
        • World
      • Law
      • Explainers
      • News 
        • All News
      • Decode 
        • Impact
        • Scamcheck
        • Life
        • Voices
      • Media Buddhi 
        • Digital Buddhi
        • Senior Citizens
        • Videos
      • Web Stories
      • BOOM Research
      • BOOM Labs
      • Deepfake Tracker
      • Videos 
        • Facts Neeti
      • Home-icon
        Home
      • About Us-icon
        About Us
      • Authors-icon
        Authors
      • Team-icon
        Team
      • Careers-icon
        Careers
      • Internship-icon
        Internship
      • Contact Us-icon
        Contact Us
      • Methodology-icon
        Methodology
      • Correction Policy-icon
        Correction Policy
      • Non-Partnership Policy-icon
        Non-Partnership Policy
      • Cookie Policy-icon
        Cookie Policy
      • Grievance Redressal-icon
        Grievance Redressal
      • Republishing Guidelines-icon
        Republishing Guidelines
      • Fact Check-icon
        Fact Check
        Fast Check
        Politics
        Business
        Entertainment
        Social
        Sports
        World
      • Law-icon
        Law
      • Explainers-icon
        Explainers
      • News-icon
        News
        All News
      • Decode-icon
        Decode
        Impact
        Scamcheck
        Life
        Voices
      • Media Buddhi-icon
        Media Buddhi
        Digital Buddhi
        Senior Citizens
        Videos
      • Web Stories-icon
        Web Stories
      • BOOM Research-icon
        BOOM Research
      • BOOM Labs-icon
        BOOM Labs
      • Deepfake Tracker-icon
        Deepfake Tracker
      • Videos-icon
        Videos
        Facts Neeti
      Trending Tags
      TRENDING
      • #Operation Sindoor
      • #Pahalgam Terror Attack
      • #Narendra Modi
      • #Rahul Gandhi
      • #Waqf Amendment Bill
      • #Arvind Kejriwal
      • #Deepfake
      • #Artificial Intelligence
      • Home
      • Coronavirus
      • Moderna Says Its COVID-19 Vaccine...
      Coronavirus

      Moderna Says Its COVID-19 Vaccine Shows 94% Efficacy In Phase 3 Trial

      From the 95 participants who developed COVID-19, only 5 people had received the vaccine

      By - Shachi Sutaria |
      Published -  16 Nov 2020 7:38 PM IST
    • Boomlive
      Moderna Says Its COVID-19 Vaccine Shows 94% Efficacy In Phase 3 Trial

      US pharmaceutical Moderna's mRNA vaccine has showed 94.5 per cent effectiveness against COVID-19 in its interim Phase 3 trials, the pharmaceutical announced on Monday. Moderna's mRNA vaccine follows the same technology as Pfizer-BioNTech's COVID-19 vaccine which announced 90 per cent protection last week.

      Notably, there are no human vaccines currently in use that follow the mRNA technology adopted by both the US-based pharmaceuticals for its COVID-19 vaccine candidates. The interim results of both the candidates show that very few participants who received the vaccine dosage developed COVID-19 symptoms.

      Also Read:COVID-19 Vaccine Candidate 90% Effective, Says Pfizer

      While Pfizer's vaccine candidate tested 94 patients with COVID-19, Moderna's interim analysis was first scheduled after 53 patients triggered symptoms of COVID-19. The Data and Safety Monitoring Board moved this number to 95 patients testing positive.

      As the trials are double-blind trials, the researchers found that from the 95 participants, 90 had received the placebo while only 5 had received the vaccine candidate. Furthermore, the interim analysis also assessed the secondary end-point of whether any participant developed any adverse reactions to the vaccine. Out of the 11 participants, none of them had received the vaccine.

      In the 95 who tested positive, 15 were over 65 while 20 belonged diverse communities (12 Latin/Hispanic, 4 African American, 3 Asian American, 1 multiracial).

      Moderna conducted phase 3 trials with over 30,000 patients in US in collaboration with US' National Institute of Allergy and Infectious Diseases, National Institutes of Health, and the Biomedical Advanced Research and Development Authority, which is a part of the US Department of Health and Human Services. Over 25,625 participants received the second dosage. Unlike Pfizer, Moderna has not announced the duration between the second dose and the onset of COVID-19 symptoms.

      All the participants were over 18 years of age while 7,000 of them were over 65. Over 5,000 participants under the age of 65 have co-morbidities such as diabetes, severe obesity, and cardiac disease which puts them at a risk of developing COVID-19. These medically high-risk groups represented over 42 per cent of the study sample.

      Emergency Use Authorization

      Moderna intends to apply to the US Food and Drug Administration for Emergency Use Authorization after around 151 participants have tested positive for COVID-19 and the second interim analysis for testing the primary endpoint of protecting from COVID-19 disease and SARS-CoV-2 is established. The company expects the efficacy data to change as positive cases accrue towards the final analysis.

      Stephan Bancel, CEO of Moderna said that this was a pivotal moment in the development of COVID-19 vaccine. "The positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease."

      A part of US' Operation Warp Speed, Moderna intends to provide all its safety and efficacy data to the FDA for its emergency use authorization at least in the US.

      Manufacturing Of Doses

      Moderna has stated that it would be in a position to produce around 20 million cases by the end of 2020. The pharmaceutical is also ready to match its goal of manufacturing 500 million to one billion doses in 2021.

      Storage

      Moderna's mRNA-1273 vaccine can be stored at 2 to 8°C for 30 days. Unlike Pfizer's vaccine which requires storing at -70 to 80°C, Moderna's vaccine will survive in existing infrastructure.

      The vaccine's stabilising capacity increased from 7 days to 30 days through the efforts of the team of scientists, Juan Andres, Chief Technical Operations and Quality Officer at Moderna, stated.

      For shipping, the vaccine requires cooling refrigerators at -20°C. The vaccine can stay stable in these containers for up to 6 months. Post shipping it needs to be kept in refrigerators at 2-8°C where Moderna expects it to be stable for 30 days. Once removed for administration, the vaccine is likely to stay stable for 12 hours at room temperature. To further ease the vaccination process, the vaccine does not require any dilutions or special handling techniques while being administered.

      Also Read:Did Pfizer Benefit From Trump's Operation Warp Speed To Develop COVID-19 Vaccine?


      Tags

      moderna vaccinemoderna94.5% efficacySARS-Cov-2COVID-19
      Read Full Article
      Next Story
      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker. Please reload after ad blocker is disabled.
      X

      Subscribe to BOOM Newsletters

      👉 No spam, no paywall — but verified insights.

      Please enter a Email Address
      Subscribe for free!

      Stay Ahead of Misinformation!

      Please enter a Email Address
      Subscribe Now🛡️ 100% Privacy Protected | No Spam, Just Facts
      By subscribing, you agree with the Terms & conditions and Privacy Policy connected to the offer

      Thank you for subscribing!

      You’re now part of the BOOM community.

      Or, Subscribe to receive latest news via email
      Subscribed Successfully...
      Copy HTMLHTML is copied!
      There's no data to copy!